Literature DB >> 23772929

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

Eleanor J Cheadle, Lauren Sidon, Simon J Dovedi, Monique H M Melis, Waleed Alduaij, Tim M Illidge, Jamie Honeychurch.   

Abstract

Entities:  

Keywords:  CD20; DAMP; cell death; lymphoma; monoclonal antibody

Mesh：

Substances：

Year:  2013        PMID： 23772929     DOI： 10.1111/bjh.12427

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

2.  Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.

Authors:  Tiansuo Zhao; He Ren; Xiuchao Wang; Pengfei Liu; Fan Yan; Wenna Jiang; Yang Li; Jing Li; John G Gribben; Li Jia; Jihui Hao
Journal:  Oncotarget       Date:  2015-09-29

Review 3.  Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Authors:  Michael J E Marshall; Richard J Stopforth; Mark S Cragg
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

4.  A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Authors:  E J Cheadle; G Lipowska-Bhalla; S J Dovedi; E Fagnano; C Klein; J Honeychurch; T M Illidge
Journal:  Leukemia       Date:  2017-11-28       Impact factor: 11.528

Review 5.  A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Authors:  Kensei Tobinai; Christian Klein; Naoko Oya; Günter Fingerle-Rowson
Journal:  Adv Ther       Date:  2016-12-21       Impact factor: 3.845

6.  Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.

Authors:  Hossein Panjideh; Nicole Niesler; Alexander Weng; Hendrik Fuchs
Journal:  Toxins (Basel)       Date:  2022-07-13       Impact factor: 5.075

Review 7.  Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Authors:  Claire Deligne; Benoît Milcent; Nathalie Josseaume; Jean-Luc Teillaud; Sophie Sibéril
Journal:  Front Immunol       Date:  2017-08-14       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.